 "Top headlines: L&T Q3 net falls; nod for Bharat Bio's intranasal dose trial")
DCGI gives permission to Bharat Biotech for intranasal booster dose trials
India's drug regulator has given permission to Bharat Biotech to conduct phase-3 clinical trial for its intranasal Covid vaccine as booster dose on participants who have been previously inoculated with SARS-CoV 2 vaccines.
India is yet to approve the use of intranasal COVID-19 vaccine BBV154 developed by the Hyderabad-based company. Read more
India to export BrahMos missiles to Philippines, signs $374-mn deal
India got its first ever export order for BrahMos missiles on Friday when the Philippines' Defence Ministry signed $374 million contract with BrahMos Aerospace Private Limited to supply an undisclosed number of missiles, military officials said.
The BrahMos Aerospace Private Limited (BAPL), an India-Russian joint venture, produces the supersonic cruise missile BrahMos that can be launched from submarines, ships, aircraft, or from land platforms. Read more
B S Yediyurappa's granddaughter Soundarya found dead in Bengaluru
Former Karnataka Chief Minister B S Yediyurappa's granddaughter Dr Soundarya V Y allegedly ended her life by hanging herself from the ceiling fan at her Vasant Nagar flat on Friday morning, police said.
According to police, the reason behind the extreme step taken by the 30-year old doctor working in a private hospital was not known immediately. Read more
L&T Q3 results: Net profit falls 17% to Rs 2,055 cr; revenue rises 11%
Infrastructure major Larsen & Toubro on Friday reported 17% fall in consolidated net profit at Rs 2,055 crore for the quarter ending December 31, 2021. It was Rs 2,467 crore in the year-ago period.
Consolidated revenue from operations rose 11% to Rs 39,563 crore as against Rs 35,596 crore in Q3FY21. Read more
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%